Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-01
2005-03-01
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
06861404
ABSTRACT:
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-βsuperfamily of proteins.
REFERENCES:
patent: 1128881 (1982-08-01), None
patent: WO 9403200 (1992-02-01), None
patent: WO 9215323 (1992-09-01), None
patent: WO 9305751 (1993-01-01), None
patent: WO 9304692 (1993-03-01), None
patent: WO 9305172 (1993-03-01), None
patent: WO 9403075 (1994-02-01), None
patent: WO 9403600 (1994-02-01), None
patent: WO 9406449 (1994-03-01), None
patent: WO 9420539 (1994-09-01), None
patent: WO 9508621 (1995-03-01), None
patent: WO 9511983 (1995-05-01), None
Jennerholm et al. Magnetic resonance imaging of the transplanted kidney. Correlation to function and histopathology. ACTA Radiologica, (1990 Sep) 31 (5) 499-503.*
Brenner et al. 1994. “Chronic Renal Failure”. In, Harrison's Principles of Internal Medicine, 13th Edition, Isselbacher et al. (eds.), McGraw-Hill, Inc., New York. pp. 1274-1281.*
Glassock et al. 1994. “Immunopathogenic Mechanisms of Renal Injury”. In, Harrison's Principles of Internal Medicine, 13th Edition, Isselbacher et al. (eds.), McGraw-Hill, Inc., New York. pp. 1292-1295.*
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, (Mar. 16, 1990) 247 (4948) 1306-10.*
Kees-Folts et al. Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. American Journal of Nephrology, (1993) 13 (5) 365-75.*
Coe et al. 1994. “Approach to the patient with diseases of the kidneys and urinary tract.” Chapter 237, In, Harrison's Principles of International Medicine. 13th ed. Isselbacher et al. (eds.) New York, McGraw-Hill, p. 1252.*
Glassock RJ. Immunosuppressive treatment in the prevention of renal failure in primary glomerular diseases. Clinical and Experimental Dialysis and Apheresis, (1981) 5 (1-2) 21-46.*
Carpenter et al. 1994. “Dialysis and transplantation in the treatment of renal failure.” Chapter 238, In, Harrison's Principles of Internal Medicine. 13th ed. Isselbacher et al. (eds.) New York, McGraw-Hill, pg. 1281.*
Tolins et al. Mechanisms of hypertensive glomerular injury. American Journal of Cardiology, (Oct. 5, 1988) 62 (11) 54G-58G.*
Ponticelli et al. Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults. Clinical Nephrology, (1991) 35 Suppl 1 S16-21.*
Klahr et al. The progression of renal disease. N Engl J Med. Jun. 23, 1988;318(25):1657-66.*
Watanabe et al. Production of hydrogen peroxide by neutrophilic polymorphonuclear leukocytes in patients with diabetic nephropathy. Journal of Clinical Laboratory Analysis, (1993) 7 (4) 209-13.*
Vukicevic et al. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). Proc Natl Acad Sci U S A Aug. 20, 1996;93(17):9021-6.*
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*
Yang et al. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrology, Dialysis, Transplantation, (1998 Aug) 13 (8) 1967-74.*
Floege et al. Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Laboratory Investigation, (1992 Apr) 66 (4) 485-97.*
Schiller et al. Focal glomerulosclerosis in the remnant kidney model—an inflammatory disease mediated by cytokines. Nephrology, Dialysis, Transplantation, (1997 Mar) 12 (3) 430-7.*
Wright et al. (1986), “Serum-Growth Hormone and Glucose Intolerance in Renal Failure,”The Lancet798-800.
Samaan et al., (1970), “Growth Hormone Levels in Severe Renal Failure,” 19Metabolism2:102-113.
Guler et al. (1989), “Effects of Recombinant Insulin-Like Growth Factor I on Insulin Secretion and Renal Function in Normal Human Subjects,” 86Proc. Natl. Acad. Sci.(USA) 2868-2872.
Avner et al. (1990), “Polypeptide growth factors in metanephric growth and segmental nephron differentiation,” 4Pediatr. Nephrol.372-377.
Border et al. (1990), “Suppression of Experimental Glomerulonephritis by Antiserum Against Transforming Growth Factor β1,”Nature, 346:371-374.
Lemann et al. (1990), “Use of the Serum Creatinine to Estimate Glomerular Filtration Rate in Health and Early Diabetic Nephropathy,” 3Am. J. Kidney Dis.236-243.
Jones et al. (1991), “Involvement ofBone Morphogenetic Protein-4(BMP-4) andVgr-1in Morphogenesis and Neurogenesis in the Mouse,” 111Development531-542.
Özkaynak et al. (1991), “Murine Osteogenic Protein (OP-1): High Levels of mRNA in Kidney,” 179Biochem. Biophys. Res. Comm.1:116-123.
Kopple (1992), “Mineral and Electrolyte Metabolism, Nutrition and Metabolism in Renal Disease,” 18Miner. Electrolyte Metab.269-275.
Özkaynak et al. (1992), “Osteogenic Protein-2: A New Member of the Transforming Growth Factor-βSuperfamily Expressed Early in Embryogenesis,” 267J. Biol. Chem.35:25220-25227.
Toback (1992), “Regeneration after acute tubular necrosis,” 41Kidney Intl.226-246.
Hirschberg et al. (1993), “Effects of Insulin-Like Growth Factor I on Renal Function in Normal Men,” 43Kidney Intl.387-397.
Yamamoto et al. (1993),_“Expression of Transforming Growth Factor β is Elevated in Human and Experimental Diabetic Nephropathy,” 90Proc. Natl, Acad. Sci.(USA) 1814-1818.
Bard et al. (1994), “Towards a Genetic Basis for Kidney Development,” 48Mech. Develop.3-11.
Miller et al. (1994), “Effects of IGF-I on renal function in end-stage chronic renal failure,” 46Kidney Intl.201-207.
Shankland et al. (1994), “Expression of Transforming Growth Factor-β1 During Diabetic Renal Hypertrophy,” 46Kidney Intl.433-442.
Tamaki et al. (1994),_“TGF-β1 in Glomerulosclerosis and Interstitial Fibrosis of Adriamycin Nephropathy,” 45Kidney Intl.25-536.
Vukicevic et al. (1994),_“Developing Human Lung and Kidney are Major Sites for Synthesis of Bone Morphogenetic Protein-3 (Osteogenin),” 42J. Histochem. Cytochem.7:869-875.
Vukicevic et al. (1994), “Localization of Osteogenic Protein-1 (Bone Morphogenetic Protein-7) During Human Embryonic Development: High Affinity Binding to Basement Membranes,” 198Biochem. Biophys. Res. Comm.2:693-700.
Yamamoto et al. (1994), “Sustained Expression of TGF-β1 Underlies Development of Progressive Kidney Fibrosis, ” 45Kidney International916-927.
Dudley et al. (1995),_“A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye,” 9Genes&Devel.2795-2807.
Hamaguchi et al. (1995), “Transforming Growth Factor-β1 Expression and Phenotypic Modulation in the Kidney of Hypertensive Rats,” 26Hypertension1:199-207.
Luo et al. (1995),“BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning,” 9Genes&Devel.2808-2820.
Vukicevic et al. (1996), “Recombinant human OP-1 (BMP-7) prevents rapid loss of glomerular function and improves mortality association with chronic renal failure,”J. Am. Soc. Nephrol..7(9):1867, Abstract A3102.
Kelly et al., Intercellular Adhesion Molecule-1-deficient Mice Are Protected against Ischem Renal Injury, J. Clin. Invest., vol. 97, No. 4, Feb. 1996, pp. 1056-1063.
Brady et al., Acute Renal Failure, Chapter 236, in Harrison's principles of internal medicine, 13thed., editors, Kurt J. Isselbacher . . . , New York, McGraw-Hill, 1994, pp. 1265-1274.
Leifer et al., Anti-ischaermic and endot
Cohen Charles M.
Sampath Kuber T.
Vukicevic Slobodon
Curis, Inc.
Romeo David
Ropes & Gray LLP
LandOfFree
Therapies for chronic renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapies for chronic renal failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapies for chronic renal failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3443274